147 related articles for article (PubMed ID: 8725865)
1. An importance of carbohydrate ingestion for the expression of the effect of alpha-glucosidase inhibitor in NIDDM.
Hara T; Nakamura J; Koh N; Sakakibara F; Takeuchi N; Hotta N
Diabetes Care; 1996 Jun; 19(6):642-7. PubMed ID: 8725865
[TBL] [Abstract][Full Text] [Related]
2. Effect of alpha-glucosidase inhibitor in combination with sulphonylurea compounds on lipid profile in patients with non-insulin-dependent diabetes mellitus.
Okada S; Ishii K; Tanokuchi S; Hamada H; Ichiki K; Ota Z
J Int Med Res; 1995; 23(6):492-6. PubMed ID: 8746618
[TBL] [Abstract][Full Text] [Related]
3. Effect of an alpha-glucosidase inhibitor combined with sulphonylurea treatment on glucose metabolism in patients with non-insulin-dependent diabetes mellitus.
Okada S; Ishii K; Tanokuchi S; Hamada H; Ichiki K; Ota Z
J Int Med Res; 1995; 23(4):279-83. PubMed ID: 7589771
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone.
Segal P; Feig PU; Schernthaner G; Ratzmann KP; Rybka J; Petzinna D; Berlin C
Diabetes Care; 1997 May; 20(5):687-91. PubMed ID: 9135927
[TBL] [Abstract][Full Text] [Related]
5. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
Chow CC; Tsang LW; Sorensen JP; Cockram CS
Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472
[TBL] [Abstract][Full Text] [Related]
6. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
Johnston PS; Lebovitz HE; Coniff RF; Simonson DC; Raskin P; Munera CL
J Clin Endocrinol Metab; 1998 May; 83(5):1515-22. PubMed ID: 9589648
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.
Hoffmann J; Spengler M
Diabetes Care; 1994 Jun; 17(6):561-6. PubMed ID: 8082525
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with acarbose: results of a Canadian multicentre study.
Rodger NW; Chiasson JL; Josse RG; Hunt JA; Palmason C; Ross SA; Ryan EA; Tan MH; Wolever TM
Clin Invest Med; 1995 Aug; 18(4):318-24. PubMed ID: 8549019
[TBL] [Abstract][Full Text] [Related]
9. Insulin versus a combination of insulin and sulfonylurea in the treatment of NIDDM patients with secondary oral failure.
Ravnik-Oblak M; Mrevlje F
Diabetes Res Clin Pract; 1995 Oct; 30(1):27-35. PubMed ID: 8745203
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group.
Dills DG; Schneider J
Horm Metab Res; 1996 Sep; 28(9):426-9. PubMed ID: 8911977
[TBL] [Abstract][Full Text] [Related]
11. The effect of a very low dose of tolbutamide combined with an alpha-glucosidase inhibitor in non-insulin-dependent diabetes mellitus.
Okada S; Ishii K; Hamada H; Tanokuchi S; Ichiki K; Ota Z
J Int Med Res; 1996; 24(5):433-7. PubMed ID: 8895047
[TBL] [Abstract][Full Text] [Related]
12. Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes.
Wolever TM; Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH
Int J Obes Relat Metab Disord; 1997 Sep; 21(9):756-63. PubMed ID: 9376887
[TBL] [Abstract][Full Text] [Related]
13. Comparison of different insulin regimens in elderly patients with NIDDM.
Wolffenbuttel BH; Sels JP; Rondas-Colbers GJ; Menheere PP; Nieuwenhuijzen Kruseman AC
Diabetes Care; 1996 Dec; 19(12):1326-32. PubMed ID: 8941458
[TBL] [Abstract][Full Text] [Related]
14. Progression of retinopathy after change of treatment from oral antihyperglycemic agents to insulin in patients with NIDDM.
Henricsson M; Janzon L; Groop L
Diabetes Care; 1995 Dec; 18(12):1571-6. PubMed ID: 8722053
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy of alpha-glucosidase inhibitor and a sulfonylurea compound prolongs the duration of good glycemic control.
Matsumoto K; Sera Y; Abe Y; Tominaga T; Ueki Y; Miyake S
Metabolism; 2002 Dec; 51(12):1548-52. PubMed ID: 12489066
[TBL] [Abstract][Full Text] [Related]
16. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
Turner RC; Cull CA; Frighi V; Holman RR
JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
[TBL] [Abstract][Full Text] [Related]
17. Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial.
Josse RG
Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S167-72. PubMed ID: 8529510
[TBL] [Abstract][Full Text] [Related]
18. Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis.
Pugh JA; Wagner ML; Sawyer J; Ramirez G; Tuley M; Friedberg SJ
Diabetes Care; 1992 Aug; 15(8):953-9. PubMed ID: 1387073
[TBL] [Abstract][Full Text] [Related]
19. No relationship between carbohydrate intake and effect of acarbose on HbA1c or gastrointestinal symptoms in type 2 diabetic subjects consuming 30-60% of energy from carbohydrate.
Wolever TM; Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH
Diabetes Care; 1998 Oct; 21(10):1612-8. PubMed ID: 9773719
[TBL] [Abstract][Full Text] [Related]
20. Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition.
Johnston PS; Feig PU; Coniff RF; Krol A; Kelley DE; Mooradian AD
Diabetes Care; 1998 Mar; 21(3):416-22. PubMed ID: 9540025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
